← Leaderboards
Afshin Dowlati
Case Western Reserve University
$11,024,361
Attributed
$11,024,361
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,024,361 · 11
By mechanism
U01$4,985,745 · 1
P30$4,380,130 · 3
K23$638,280 · 1
U54$541,528 · 2
R21$377,579 · 1
M01$101,099 · 3
Top collaborators
No co-investigators on record.
Most similar at Case Western Reserve University
Same institution · by research overlap
- John J Pink$2,581,828
- Scot C Remick$11,938,221
- Charles Leslie Hoppel$9,267,801
- Richard F Silver$3,065,819
- Stanton L Gerson$68,151,957
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsProgramsClinical ResearchClinical TrialsInstitutionResearch PersonnelCancer PatientMolecularBaseEnsureMonitorResourcesLeadershipFundingEnrollmentCancer TherapyScientistSourceLinkCancer CenterImageCore FacilityLaboratoriesPharmacologic Substance
Grant awards (30)
Clinical Protocol and Data Management$1,014,134
P30 · FY2025 · CA · contact PI
Developmental Core$136,920
U54 · FY2024 · CA · contact PI
Developmental Core$102,862
U54 · FY2023 · CA · contact PI
Developmental Core$100,582
U54 · FY2022 · CA · contact PI
Developmental Core$100,582
U54 · FY2021 · CA · contact PI
Developmental Core$100,582
U54 · FY2020 · CA · contact PI
Identification and Targeting of Chemotherapy Refractory Small Cell Lung Cancer$168,779
R21 · FY2019 · CA · contact PI
Identification and Targeting of Chemotherapy Refractory Small Cell Lung Cancer$208,800
R21 · FY2018 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$841,154
U01 · FY2013 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$594,035
U01 · FY2012 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$746,424
U01 · FY2011 · CA · contact PI
CLINICAL TRAILS CORE$680,094
P30 · FY2011 · CA · contact PI
CLINICAL TRAILS CORE$742,274
P30 · FY2010 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$719,853
U01 · FY2010 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$772,307
U01 · FY2009 · CA · contact PI
CLINICAL TRAILS CORE$704,861
P30 · FY2009 · CA · contact PI
CLINICAL TRAILS CORE$758,827
P30 · FY2008 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$751,074
U01 · FY2008 · CA · contact PI
Translational Assess. of Kinase Targets in Lung Cancer$100,440
K23 · FY2008 · CA · contact PI
CWRU/UHICC Phase I Trials of Anticancer Agents$560,898
U01 · FY2007 · CA · contact PI
CLINICAL TRAILS CORE$416,454
P30 · FY2007 · CA · contact PI
Translational Assess. of Kinase Targets in Lung Cancer$134,460
K23 · FY2007 · CA · contact PI
STAFF INVESTIGATORS$63,486
P30 · FY2007 · CA · contact PI
Translational Assess. of Kinase Targets in Lung Cancer$134,460
K23 · FY2006 · CA · contact PI
REBECCAMYCIN AND OXALIPLATIN FOR SOLID TUMORS$16,493
M01 · FY2006 · RR · contact PI
Translational Assess. of Kinase Targets in Lung Cancer$134,460
K23 · FY2005 · CA
REBECCAMYCIN AND OXALIPLATIN FOR SOLID TUMORS$21,695
M01 · FY2005 · RR
REBECCAMYCIN IN UNRESECTABLE OR METASTATIC HEPATOBILIARY CANCERS$19,578
M01 · FY2005 · RR
Translational Assess. of Kinase Targets in Lung Cancer$134,460
K23 · FY2004 · CA
Rebeccamycin in unresectable or metastatic hepatobiliary cancers$43,333
M01 · FY2004 · RR